Imperial Brands PLC (IMB) Earnings Call Transcript & Summary
May 19, 2020
Earnings Call Speaker Segments
Dominic Brisby
executiveGood morning, and welcome to the presentation of our 2020 interim results. I'm Dominic Brisby, Joint Interim CEO, and Joerg Biebernick is here with me — he'll be presenting as well today — and our CFO, Oliver Tant, is also with us. Back in early February, the Board asked Joerg and me to lead Imperial, and since then the two of us have been working alongside Oliver on five key areas: protecting the health, safety and well-being of our people; keeping supply flowing to customers; sharpening our focus on tobacco performance; right sizing investment behind our next generation products; and strengthening the balance sheet. Throughout this presentation, we'll lay out the progress achieved in each of those areas. Joerg and I will give an initial overview, then hand over to Oliver, who will take you through the financials, our revised approach to capital allocation and the outlook. After that we'll cover divisional performance before we take questions. Let me begin by discussing how we've managed the business through the coronavirus — starting with the way we've protected the health, safety and well-being of our people. We have more than 32,000 employees around the world. They are the lifeblood of the business, and we value everything they've been doing in these challenging times.
Dominic Brisby
executiveAcross every market where we operate, we have carefully adhered to guidance from governments and public health authorities, and that will remain our approach. For a while now, significant portions of the business have been functioning remotely. In places where staff must be present on-site — our manufacturing facilities, for example — they are going about it in a manner that puts their health and well-being first, with social distancing and hygiene protocols being strictly observed. The diversified character of our manufacturing and supply chain has served us well. We run 38 factories, and the manufacturing teams deserve great credit for keeping the vast majority of them running right through the crisis. Some smaller factories were temporarily shut, chiefly in cigars, but those are now operating again, albeit at reduced capacity, which could have an impact on supply down the road. Up to now, we have continued to serve customers, and across most key product lines we generally hold 8 to 10 weeks of finished goods. Our people have performed remarkably, and I know many of them are listening in today. On behalf of the Board, Joerg, Oliver and myself, I want to say that leading you at this moment makes us immensely proud.
Dominic Brisby
executiveWe really appreciate all the incredible support and dedication. Now, on to our customers and consumers. Tobacco sales during the first half have been fairly stable. Restrictions on international travel have hurt duty free and travel retail sales, though that was more than offset by some temporary stockpiling in March, giving a net upside to revenue and profit of around 1% for the half. Looking ahead, it seems inevitable that we'll keep seeing a significant reduction in international and cross-border travel for the rest of this year, so we're very unlikely to see this part of the business improve in the second half. We've also set out a number of risks related to COVID-19 in the RNS, including the impact on consumer trends and regulation, and we will keep actively monitoring them. Let's now look at how we have reshaped our focus in the first half, and I will hand over to Joerg.
Joerg Biebernick
executiveThank you, Dominic. While we did meet the revised expectations we set for the first half, these results are obviously disappointing. What the figures don't capture, though, is the progress being made as we refocus the business — notably by taking a 'back to basics' approach to tobacco. Thanks to our sharper focus on in-market execution, tobacco share has grown for the group as a whole and in 7 of our 10 priority markets. Underlying pricing has held up well, though some temporary adverse market mix and the effects of downtrading have partly offset that. The tobacco business has sound fundamentals, and we expect continued growth over the medium term, with high margins and strong cash flows. In NGP, we have been taking steps to right-size our investment and resources in light of the uncertain environment and last year's disappointing performance. We've reset our plans, which has meant concentrating the most effective investment behind blu and cutting back in areas that weren't working as well as we'd have liked in both the U.S. and Europe. Last month, we submitted PMTAs to the FDA for a range of myblu products. We still believe myblu has a key role to play in realizing our goal of providing adult smokers with a range of potentially less harmful products.
Joerg Biebernick
executiveImproving returns is what we're focused on for this year, along with reinforcing the footing of our NGP business and keeping a spread of options open for growth down the road. Steps have also been taken to make the business and its balance sheet stronger, with the cost base across every element of discretionary spend challenged rigorously so that profitability improves. Cash delivery has been addressed in much the same way. A new three-year credit facility was announced in March, and last month we reached agreement on selling our premium cigar business — a major achievement given the circumstances we're in. That disposal makes the business simpler still, and the proceeds will go toward speeding up debt reduction. Today's announcement that we are rebasing the dividend by a third will also help de-leverage the balance sheet faster. The board recognizes how important growing dividends are for shareholders, and we are committed to a progressive policy that grows from the revised base, while making the business stronger for the future and underscoring its defensive characteristics. Oliver will give you some further color on this later. Before I hand over to Oliver, I'd like to briefly touch on our sustainability strategy, which centers on three key areas defining how we manage our environmental, social and governance responsibilities — maintaining a sustainable tobacco supply, developing NGPs that are potentially less harmful to health, and running our operations responsibly, keeping our people safe and giving them a rewarding environment.
Joerg Biebernick
executiveIn the current climate, putting attention on our employees and how we operate is obviously particularly pertinent, and we keep making sure everyone on our teams can carry out their duties without risk. We're tracking official guidance carefully in every market where we operate, so that when lockdown restrictions loosen, our staff get full backing for whatever return they make to their usual workplace — be that out in the field, at an office, or in a factory. As things stand right now, delivery against our ESG KPIs has not been impacted by the coronavirus. That said, certain particular initiatives planned for this year have unavoidably been hit, among them progress on the independent environmental assessment of a blu device. That piece of work continues, and we'll make every effort to have it finished within this financial year. Our commitment to the ESG agenda is undiminished, and at present we are working on developing KPIs covering all five of our priority ESG issues. It is our aim to have these finalized alongside new CEO Stefan Bomhard in the summer and put into practice in the new financial year. Thank you. Over to Oliver now.
Oliver Tant
executiveThanks, Joerg, and good morning to all of you. Looking at it from an earnings standpoint, what these results show is the action we're taking during 2020 to offset the weak returns delivered by the NGP business in 2019. Of the 8.5% drop in operating profit for the half, more than 6% is tied to one-off charges — the write-down of flavored pods in the US, slow moving inventory more broadly, and an impairment on certain vapor intellectual property assets. That said, our performance is beginning to show the renewed focus we're putting on the tobacco business as well. Tobacco volumes gained from a stronger showing in the AAA division against a weak comparator, and they also reflect the continued share improvement we're delivering across many of our priority markets. As we moved toward the end of the period, we saw some inventory build tied to COVID-19, although we expect that to fully unwind in the second half. Group share overall rose 15 basis points in the 12 months to February and 40 basis points over the last 6 months. Tobacco revenues came in 0.9% higher, helped by a relatively strong volume performance and by pricing. That was partly offset, though, by some adverse mix, which I'll explain in a moment.
Oliver Tant
executiveLower NGP revenue is down to destocking plus the category slowdown across the US and Europe, though sell-out rates have held up fairly well, and blu is keeping share in a number of markets. For the period, total revenues fell 0.9%. EPS landed a touch above what we had anticipated, and I'll go through the drivers in a moment. Cash conversion for a 12-month period came in at 103%, above expectations, thanks to NGP write-downs that hit profit but not cash, along with a working capital inflow benefit that will reverse in the second half. Constant currency EPS for the half year was down just over 9%, a little better than guidance. That came from a 2% improvement in trading, partly offset by a 1% headwind from a £19 million impairment of NGP intellectual property assets, which our original guidance did not include. It stemmed from reviewing our IP against our updated product launch plans. We estimate that roughly 1% of the trading benefit in the first half was COVID-19 related — the net effect of a decline in duty free and travel retail, offset by some consumer & customer stockpiling in March. Tobacco volumes were down only 0.5% in the half.
Oliver Tant
executiveThe main factor here was the rebound in the Middle East and Southeast Asia — each of those regions had a soft first half last year because of when regulatory changes landed and because of distributor disruption. Because of that, tobacco volumes in AAA rose 4%. US volumes came in ahead of what we expected, thanks to strong promotional activity in Q2, which helped us gain share, along with some trade pull tied to COVID-19 and the timing of normal industry inventory movements. Europe performed roughly in line with the broader market: higher German private label volumes and some stockpiling in March were largely offset by a double-digit drop in Ukraine, although that last item barely affected revenues or profit. Underlying pricing was strong, but several discrete temporary mix headwinds have partly offset it, and I'll explain those. The good pricing came mostly from MPIs in the second half of 2019 in key markets — notably the US, UK and Germany. We also gained from a carryover of Australian stock profit that wasn't realized at the end of last year. Market mix was negative during the period. We posted strong volume growth in the Middle East against a weak comparator, where revenue per thousand is significantly below the group average.
Oliver Tant
executiveOn the other side, the drop in volumes in Australia — which is among the markets with the highest value — came from illicit trade expanding, and that has more than cancelled out the gain from the share growth we recorded recently. A product mix headwind also hit us in the half. That came mainly from downtrading in Australia as the fifth price tier expanded, together with weaker Backwoods sales in the US, and that latter one is already showing some improvement early in H2. For the half, tobacco net revenue rose by just under 1%. NGP net revenue fell by 43%, which reflects destocking in Europe and the US, partly offset by heated tobacco growth in Japan. All told, at constant currency revenue declined by 0.9%, and by 1.7% at actual rates, following a 0.8% currency headwind. Tobacco profits dropped by £12 million, or 0.7%, in the half, mainly because of cost phasing, which I'll cover in more detail on the next slide. Write-downs of inventory and IP assets tied to NGP cut profit by £95 million. Slightly more than half of that is tied to the value of flavored pods in the US, with another £28 million provided against slow-moving inventory, reflecting our revised growth expectations for the vapor category in our business.
Oliver Tant
executiveThere was also the £19 million impairment of intangible assets that I referenced earlier. The decline in reduced-risk product trading income mirrors softer sales and gross profit after destocking. That effect is partly countered by A&P and overheads, which are down both year-over-year and sequentially against the second half of last year, since we cut back on less effective investment. The cut was larger in the second quarter, as we worked through the burden of spend committed at the close of last year. Growth in Logista's contribution to group operating profit mirrors lower eliminations, driven by cycling the reduced-risk product inventory build from the first half of 2019 that supported market launch activity. Group adjusted operating profit, logistics included, fell 7.7% in constant currencies and 9.3% at actual rates. I've already walked through what drove the rise in tobacco net revenue, which underpinned a 1.3% gain in gross profit. That gain did not carry through to better operating profit, because operating costs rose, largely for timing reasons. Consistent with our sharper focus on tobacco, we have gone back over our investment plans and redirected certain initiatives. Consequently, promotional activity has been rephased into the latter portion of H1, especially in Europe, so trade spend makes up a bigger share this half than it did last year.
Oliver Tant
executiveThe tobacco segment's overheads have likewise been weighted more toward the first half in 2020, which mirrors the greater priority the sales force has given this area while we resize NGP. Costs on the production side tied to EUTPD2, together with the fresh track and trace rules, have contributed to that cost shape as well. Last, although finished goods inventories meant supply was for the most part unaffected, the hit to our supply chain from government-mandated shutdowns at our cigar sites in Honduras, Puerto Rico and the Dominican Republic resulted in some production costs going under-recovered in H1. Each of the three sites reopened within just a few weeks, but a return to full capacity is unlikely as long as the new COVID-related safety procedures stay in force. We have sharpened our attention further on cost and cash opportunities throughout the business, placing still heavier emphasis on how we manage investment and working capital. Beyond cutting NGP investment and overhead spending, we have also begun paying still greater heed to cost reduction initiatives so as to lift returns and soften the profit hit from the inventory write-downs. That has covered travel restrictions, recruitment freezes, cancellation of discretionary expenditure and postponement of non-essential capital expenditure. In parallel, we keep pursuing more efficient working capital usage to strengthen cash generation further.
Oliver Tant
executiveFor the trailing 12 months, cash conversion got a boost from temporary working capital inflows tied to changes in our production schedule. Going forward, COVID-19 has created some temporary working capital shifts as we build contingency stocks to support the supply chain, and we expect those to unwind in the second half. We continue to monitor closely every aspect of working capital, including the timing of excise payments, which are a fundamental part of the positive working capital inflow we benefit from under our cash pooling arrangement with Logista. While the COVID-19 effect in H1 was limited, the situation keeps evolving, so we've undertaken extensive stress testing of our liquidity needs and financial resources. We have modeled a range of situations, including recessions, with differing profit impacts across a span of time periods, as well as temporary and permanent reductions in our manufacturing capacity. Our testing shows that, from a solvency perspective, we have the ability to absorb a significant systemic shock. We recently agreed a new €3.5 billion multi-currency revolving credit facility, which is undrawn, and have taken further steps to improve liquidity by securing an additional €1.7 billion of committed 18-month bank facilities, of which €1.1 billion was secured after the COVID-19 lockdowns.
Oliver Tant
executiveWe’ve likewise secured funding via the Bank of England’s COVID Corporate Financing Facility. Our company’s liquidity rests on solid operating cash flows generated by tobacco—both directly within the business and through our cash pooling arrangement with Logista. In addition, we hold a robust committed financing position, with no near-term funding needs, and the steps taken to secure efficient cost and cash management and to bolster liquidity have made the group more resilient. The Premium Cigars transaction was complicated, and we are extremely thankful for our teams’ hard work and persistence, which got it across the finish line—an even bigger accomplishment given today’s conditions. The multiple of just under 12 times EBITDA acknowledges the luxury character of the business and its international growth profile. This sale advances us further toward our goal of becoming a leaner, more agile organization. Cash proceeds will be used to reinforce the balance sheet, cutting net debt to EBITDA by roughly 0.2 times, with full-year dilution of approximately £0.06, equal to 2% of full-year 2019 earnings. Since the transaction is now expected to close in July, I anticipate dilution in FY 2020 of about 0.3%. We also expect to record a non-cash credit to our foreign exchange reserves, which will partly offset the non-cash impairment charge we have taken so far.
Oliver Tant
executiveAs per accounting rules, this gets recognized when completed. We've been concentrating on a deleverage plan for a while now. And although the Premium Cigar sale brings us nearer to our net debt to EBITDA target range of 2.0 to 2.5 times, over the last couple of years we haven't managed to pay down debt quite as fast as we would have preferred. We also acknowledge that investor appetite for debt has diminished over the past year or so. So, even though our tobacco business model continues to be strongly cash generative, we have adjusted our capital allocation priorities to re-balance deleverage and shareholder returns, thus giving greater balance sheet resilience and flexibility. This is not — and I'll say it again, not — a decision prompted by worry about future cash flows or by COVID-19, even though the uncertainties COVID-19 has created reinforce how important a strong balance sheet is. This is about speeding up the pace of debt reduction. With that in mind, the board has chosen to rebase the dividend by one-third, which means the total dividend for this financial year will be £1.377 per share. We will keep a progressive dividend policy as set out last year, under which the dividend will grow annually from the re-based level, taking into account the underlying performance of the business.
Oliver Tant
executiveCutting the dividend frees up roughly £650 million a year, and that money will go toward paying down debt faster. We're aiming to bring gearing down to the lower end of our 2.0 to 2.5 times target range, and we expect to get there by the end of 2022. The new policy also gives us more flexibility on shareholder distributions — once we've hit our target leverage, there's potential to return surplus cash flows via share buybacks or special dividends. Our overall objective hasn't changed. We'll keep investing in the business to support delivery of strong and sustainable operating cash flows. That investment will sit within clear return hurdles, with a greater emphasis on evaluating and mitigating risk. As a result, in the short term we expect any investment to be prioritized behind tobacco, where the investment risk profile is lower. We'll also actively manage the capital base, looking for opportunities to realize value and streamline the business. We'll update the market on our investment priorities once our new CEO, Stefan Bomhard, has arrived and has had the chance to assess his strategic priorities and set out a vision for the future of the business. Our revised capital allocation priorities continue to recognize the importance of growing dividends for shareholders, with a rebased pay-out level giving the business greater financial flexibility to strengthen the balance sheet.
Oliver Tant
executiveAs we mentioned in the AGM statement back in February with our revised guidance, the current analyst consensus for the whole year points to EPS decreases of 2% on a constant currency basis, before an FX headwind of roughly 3%. Our underlying business is still broadly steady, reflecting tobacco's defensive characteristics, but we have spotted downside risks to trading in H2. COVID-19's impact was fairly contained during our first half, yet over the past few weeks we have begun to observe more meaningful effects emerging, most notably in duty free and travel retail, where tight restrictions on cross-border and international movement have caused a substantial downturn in that business. Only a modest share of volume is being repatriated to domestic markets, and with cuts to both business and leisure travel likely to last for a while, at present we are not factoring in any recovery across the second half. We have likewise observed shifts in consumption and purchasing behavior. For instance, during the first half, once lockdowns came into force, we saw some downtrading, and that trend has picked up pace, with stronger demand for value formats like fine cut tobacco and big box products. Recessionary pressures could intensify this, although we are comparatively well positioned, given that our portfolio has less exposure to premium products.
Oliver Tant
executiveEven though every one of our cigar sites has reopened now after the government-mandated shutdowns in the first half, social distancing rules and other COVID-related restrictions have created cost inefficiencies and cut production capacity for the time being. By the end of June, we've assumed our cigar facilities get back to full capacity. We expect higher manufacturing costs as a result of these disruptions. We've also assumed there won't be a second spike in COVID infection rates, which would cause further disruption in other parts of manufacturing and the supply chain. It's hard at this early stage to gauge how much these factors will hit our business, but right now we're assuming a low single-digit impact to EPS. Beyond that, our full-year results will now also include the £19 million intellectual property asset impairment, a 0.6% hit to EPS, which was recognized in the first half but wasn't part of our previous guidance. We also expect roughly 0.3% dilution from the Premium Cigars disposal. At current rates, we also expect currency to have a neutral effect on our earnings per share. Thank you. I'll now hand back to Dominic, who will walk you through divisional performance for the Americas and AAA division.
Dominic Brisby
executiveThanks, Oliver. In the US, we grew cigarette share as we kept managing the portfolio so it competes actively across every price segment. We got solid pricing throughout the portfolio, with cigarette price/mix a little above 5%. That gain, though, was offset by cigars — weaker Backwoods revenue and stronger sales of lower-priced Dutch — which pushed portfolio mix negative. Backwoods sales keep being hit by supply constraints and rising competition in the natural leaf wrapper segment. We're already on it, and H2 has already shown a marked improvement, helped by more promotional activity, additional limited editions and wider distribution. The familiar NGP challenges inevitably weighed on NGP revenue and profit. We've cut our vaping investments substantially, moving from nationwide above-the-line, out-of-home advertising to far more targeted spend with selected high value distributors and retailers. As you heard, our PMTA applications for myblu have been submitted, and we now look forward to working with the FDA as it develops and enforces an evidence-based regulatory policy. Excluding the one-off charges in the period for inventory write-down on vapor, underlying profit growth was 1.4%. In AAA, our sales performance benefited from the normalization of shipment timings in the Middle East following the regulatory changes last year.
Dominic Brisby
executiveThese results also capture the anticipated benefit in Australia tied to last year's sell-through of duty-paid inventory before the September price increase. Delivery of net revenue was partially offset by an unfavorable geographic mix, caused by rising volumes of lower-margin product in the Middle East and by expansion in Australia's economy segment. We kept investing behind NGP in Japan, lifting sales in both nicotine-free vapor and heated tobacco, with wider distribution of Pulze through two nationwide convenience chains. Adjusted operating profit took a hit from the geographic mix and from the larger investment in Pulze after its May launch last year. We gained share across every priority market in the division, actively shaping the portfolio to match shifting demand toward value formats in brands such as West and P&S, along with premium brands such as Davidoff. In the US, simplifying the portfolio has let us boost investments behind our core brands while the tail creates less of a drag. In Australia and Japan, we are answering growing consumer demand for value offerings via P&S and West. In Russia and Saudi, share performance has come from optimizing our sales force activities and adding line extensions to meet demand in the king and queen size ranges for Davidoff.
Dominic Brisby
executiveThanks. Joerg, over to you now.
Joerg Biebernick
executiveThank you, Dominic. In Europe, results took a hit from reduced NGP revenues and the related write-downs, and those factors outweighed the gains we saw in tobacco revenues. Our approach continues to be one of balancing the priority market share positions we hold against optimizing financial returns, so that we deliver quality growth in the right markets, with the right brands. We picked up share in Italy and Spain, where blonde tobacco growth is now outweighing the drag coming from dark formats, and we improved sequential share in the UK and France. Tobacco volumes fell by 3%. That broadly tracks the trend seen across the wider market, with some help from accelerated buying around COVID-19 and strong private label sales in Germany offsetting declines in the Ukraine. Tobacco revenues rose by 0.5%, helped by positive pricing in several markets, including a carry-over of pricing in Germany and the UK from last year. That offset the hit from lower global duty free and travel retail sales caused by virus-related travel restrictions. On the whole, divisional net revenue declined 2%, driven by a 56% drop in NGP sales to £30 million, which reflects destocking in the supply chain and weakness in the category. On an encouraging note, our blu share in several markets, such as the UK, France and Italy, held relatively stable, which reinforces our view that the blu proposition is competitive.
Joerg Biebernick
executiveThe sales decrease mostly comes from destocking along with a bit of softness in category size. After our initial 2019 launches, we also broadened distribution for our modern oral nicotine products, and we've seen solid growth in Germany and Austria. Operating profit came in 6.7% lower. That mirrors reduced NGP revenues and write-down effects, as well as the differing half-on-half phasing of A&P across key European markets such as the UK and Germany, where promotional activity has been weighted far more toward H1 than was the case last year. In the UK, we introduced Lambert & Butler branded fine-cut tobacco, and that product, alongside a number of bigger value offerings, is off to a strong start and is helping drive sequential share growth against the second half of 2019. Even so, share remains down on an MAT basis after last year's declines. In Germany, we're putting additional investment into reshaping the portfolio, headed by JPS and West, with emphasis on value formats. Our share in France is likewise growing sequentially versus the second half of fiscal year 2019, helped by a stronger sales team emphasis on tobacco and wider asset brand distribution. In Spain, we've picked up share in blonde cigarettes and fine cut after last year's successful launch of Horizon and solid progress on West, Ducados and Fortuna.
Joerg Biebernick
executiveGains in Italy have come about through JPS's ongoing success. To sum up, looking purely at the financial side, this six-month stretch has clearly brought real difficulties, and while we've cut our expectations for the year to account for what COVID-19 could do, we're still moving forward and staying focused on making performance stronger. Market share growth across the group as a whole mirrors our back to basics approach and a fresh push for growth in tobacco, which forms the bedrock of our business and gives us the foundation for long-term growth opportunities. The decisive steps we're taking to right-size our NGP operations and secure optionality going forward are giving us a stronger platform for growth, and our recent PMTA filing in the US has added to that optionality. Selling Premium Cigars underscores our focus on simplifying the business and realizing value for shareholders, with the proceeds speeding up deleverage and making our balance sheet more resilient. That our business has kept manufacturing, distributing and selling our products, largely without coronavirus getting in the way, is thanks to the hard work, flexibility and commitment of all our people. We're immensely proud of their ongoing efforts.
Joerg Biebernick
executiveThanks a lot for tuning in. At this point we'd be glad to take your questions. Since we're all in separate places, Peter Durman, our Director of IR, is going to help coordinate the Q&A. I'll turn things back to the operator so we can get the question-and-answer session going.
Operator
operatorOperator script. The first question is from Owen Bennett at Jefferies. Your line is open, and you may go ahead.
Owen Bennett
analystGood morning, everyone. I hope you're all doing well. I've just got the one question, and it relates to the COVID guidance. In that guidance, you discuss downtrading and note that you have limited premium exposure. But how do you view the risk of downtrading from value into illicit, something we saw previously after 2008? Thank you.
Peter Durman
executiveThanks, Owen. What I'll do is try to coordinate the questions by distributing them to everyone — since we're all in different places, just so you know. So, on that particular point, I'll turn to Dominic for his perspective.
Dominic Brisby
executiveYeah. Hi, Owen. What's interesting is that throughout COVID, if anything, we've actually witnessed a decline in illicit trade, purely because so many borders were shut. So thus far, there hasn't been a significant effect. And the bulk of our modeling indicates it's not likely to have a significant effect down the road once lockdowns become less severe. That said, it's worth noting that downtrading is happening. And we're attempting, as much as we can, to capitalize on that, which is among the reasons — and our achievement in doing so is among the reasons why we've managed to increase share in 7 of our 10 priority markets, as we ensure we tailor our offerings to what consumers want. And since consumers are concentrating more on this area, it's been vital that we offer them enough, which is among the reasons why we've managed to grow.
Owen Bennett
analystThat’s great. Thank you so much.
Operator
operatorGaurav Jain from Barclays has the next question. Go ahead.
Gaurav Jain
analystMorning, everyone. I trust all is well. Three questions from me. First, regarding the US volume guidance you provided at CAGNY of minus 5% to minus 6% for FY 2020: your 1H volumes came in at minus 2%, and that likely included some reversal of the inventory build that occurred at the end of 2019. So how do you view your FY 2020 US volumes? That is question one. Question two concerns your NGP losses, which were fairly large in the first half. You are laying out many ways to control those losses, yet you still speak of investing in NGPs, and you have three categories: blu, Pulze and oral nicotine pouches. Which of those categories would you be investing in? And third, just on the volume and price mix dynamics: your volumes were much better while price mix was much worse, but COVID only hit in March. So for 2H, should we expect an even worse price mix? Thank you.
Peter Durman
executiveThanks, Gaurav. Here's what I'll do: Dominic, I'll have you handle the first question about US volume guidance, and Oliver, I'll ask you to take the second two — the ones on NGP, the investment side and the losses, and also the volume-price mix dynamics.
Dominic Brisby
executiveHi, Gaurav — thanks for asking. So on the US, you're correct that at CAGNY we indicated the total market would likely decline by roughly 5% or 6%. That remains broadly true. Actually, if anything, we'd probably tweak that a bit and say we now expect total markets to be down about 5%. And when we discuss the US, it's important to make clear that our strong focus is on gaining market share there. In FY 2019, we increased share in the USA with that group of brands for the first time in decades. We've also gained share at the half year, and that's something we'll keep concentrating on as we move forward.
Oliver Tant
executiveGood morning, Gaurav. Let me begin with the NGP question. Clearly, there are three categories we're focused on: OND, heated tobacco, and EVP. It's fair to say that where investment focus on OND is concerned, that really hasn't shifted. Two considerations have driven us in heated tobacco and EVP. The first is that we're moderating some of our longer-term investment decision making so as to focus on things with shorter-term paybacks, and that is capping the level of investment in both heated and EVP. We've also reviewed, particularly with regard to EVP, the returns coming from different consumer groups. Within EVP we see a very clear community of loyal consumers whom we continue to focus on and support. But there is a group of less loyal consumers whose consumption patterns are more fickle, where the economics right now simply don't make sense for us. So we are curtailing investment, particularly in EVP, around that second group. Just on guidance, you can see from our numbers that in the first half we incurred a loss of around about £220 million, of which £95 million was write-downs principally relating to decisions that were made in FY 2019.
Oliver Tant
executiveSo the underlying performance in the first half came in at roughly a £135 million loss. We're working through two things: the benefit of higher sales as we emerge from a stretch where we'd destocked the trade across several products — EVP especially — and better sales performance in that second half, which will bring us extra gross profit. Alongside that, with the investment refocus I mentioned, we're bringing down A&P and overhead levels. Broadly, you can expect that to have an impact of around £75 million on our overall numbers, to the benefit, in the context of the second half. So if you start from £125 million and run the arithmetic off that base, you'll get a sense of what we're expecting in the second half — which I think differs somewhat from the figures in your note this morning. Then on value price margin — the price mix impacts — we saw, I'd say, pretty good pricing in the first half on gross pricing. It was roughly 6.7%. That came from price increases made in the latter part of last year, which, obviously, when rounded against HY1 2019, give us a benefit in H1 2020.
Oliver Tant
executiveWe anticipate some pricing movement during the second half. There will be fewer market-driven mix problems than we experienced. Our volumes in the Middle East and North Africa recovered very strongly in the first half. As we reach the second half, performance is largely settling into a fairly steady pattern. Consequently, market mix has a much smaller effect in the second half. Obviously, given what we've discussed regarding COVID, one risk we'll need to manage in the second half is possible downtrading where product mix is concerned. However, we're mostly basing our assumptions on levels comparable to the first half, reflecting expectations such as stronger Backwoods performance, which we've seen and which you'll have noticed in some third-party commentary about our MMC volumes in the US market in April.
Gaurav Jain
analystSure. Oliver, could I just follow up on that decrease in NGP losses? So what you're saying is that on an underlying basis, losses will fall by £75 million in 2H…
Oliver Tant
executiveLooking at it on an underlying basis.
Gaurav Jain
analystSo yes, the second-half losses are going to come in at roughly £50 million. And if I use that as the run rate going into next year, then basically what you're saying is that NGP losses in FY 2021 will be about £100 million?
Oliver Tant
executiveNo, I'd say that's likely going a bit too far. What we're observing is that during the next six months, performance in that business will strengthen. So I think we'll need to wait and see how things develop across those six months. It's somewhat premature to begin providing guidance on what FY 2021 will entail. We'll address that later in the year. And obviously, Stefan's direct input will be available at that point as well, regarding the priorities he wishes to set. But what we're indicating is that, generally speaking, we're anticipating that level of curtailment. We've witnessed a significant reduction in Q2 of H1. And we anticipate that trend carrying on through Q3 and Q4, with Q4 performing better than Q3. If you were to — if I were modeling, I would, generally speaking, assume that's roughly the magnitude of what we're expecting in NGP during the second half.
Gaurav Jain
analystThat is quite straightforward. Thank you.
Operator
operatorMichael Lavery from Piper Sandler is up next, and his line is open — go ahead with your question.
Michael Lavery
analystGood morning. Thanks. Could you speak to something — when you mention that following the dividend cut, you'll put debt reduction first, what sort of room, if any, should we anticipate for things such as buybacks? Is it simply going to be opportunistic? Has it been ruled out? Is it just a smaller component? A bit more detail on that would help. Then, regarding the second-half outlook, how much can you put numbers around how to consider duty free or downtrading? And what margin effect, if any, arises when a duty free sale shifts to one in a local market?
Peter Durman
executiveThanks, Michael. I think what I’ll do is have Oliver answer both of those: the dividend question and the question about the 2% to 3% outlook and downtrading.
Oliver Tant
executiveStarting with the dividend question — to be very clear, we've been focused on deleverage for some time. And even with the disposal of PCD, which will deliver roughly a 20 basis point improvement in our net debt to EBITDA numbers, we have not reached the level of deleverage over the past couple of years that we would have liked. The board firmly believes our priority should be addressing balance sheet risk issues and creating flexibility for the businesses going forward, and that is our priority. So for the next couple of years, the priority will be debt paydown rather than share buybacks. Obviously, once we reach the end of the period we anticipate it will take to get to those revised ambitions around net debt to EBITDA at the lower end of that range, other options for shareholder returns will be open to us. We clearly will want to keep investing behind the business and supporting the strategy that Stefan has developed over that period. But we'll revisit shareholder returns when we get to 2022. I think the challenge with share buybacks is that, from a board perspective — and we've seen a greater level of shareholder sensitivity around balance sheet risk emerge, pre-COVID — obviously, it's been exacerbated by COVID — but we certainly saw evidence pre-COVID.
Oliver Tant
executiveThe issue with buybacks is that they fail to tackle that concern. And the board made it clear they hold the view that this ought to be our near-term priority. And regarding your second question about price mix dynamics, and on just — that was specifically…
Peter Durman
executiveYes, that concerned duty free, the shift toward lower-priced products, and how that factors into the H2 outlook.
Oliver Tant
executiveSure. The real difficulty here is gauging the scale of this, and that means looking at how long international travel stays disrupted by the crisis we're in right now. When we set guidance at the upper end of that range, what we're assuming is that no recovery shows up before the close of September — in other words, the remainder of this year takes the hit. Obviously, if that situation clears sooner, the disruption's effect will be correspondingly smaller. And as a matter of fact, a recovery that came very fast would be comparatively far, far more contained. Another thing you have to bear in mind while estimating the impact: we don't anticipate those consumers simply going without. It's just that they won't do their buying via international travel. They'll make those purchases in their home markets, where in lots of cases margins could even be better, since the pull toward buying duty free or in travel settings comes from a value-driven dynamic. Part of our difficulty is getting a really clear handle on how big that shift of purchasing back home will be. But broadly speaking, under the more negative scenario where this affects our business all the way to the end of September, we'd picture the total effect at roughly a touch above 1%.
Oliver Tant
executiveThe effect on price mix might actually end up being slightly positive, in a counterintuitive way, since even though volume will be lower, the net revenue it sells at will, in all likelihood, be a bit higher.
Michael Lavery
analystAlright, thanks a lot.
Operator
operatorNico Von Stackelberg from Liberum is up next with a question. Your line is open.
Nico von Stackelberg
analystHello, everyone, and thank you for the questions. I have a quick question about Germany. It appears some investment was made in that market. You commented on that. However, the performance fell short of expectations. I was wondering why that was. Is there any comment? Is it simply too early to tell? A related question: it sounds like some investment went into the UK year-over-year. That confuses me a bit, because I thought this was more of a market being run for cash, broadly speaking. We have seen share declines and pricing be supportive, which suggests it is being run for cash. So, why <<inaudible>>. I have a quick question about cash flow for the full year, please. Last year, free cash flow was £2.4 billion. A few one-offs were called out before, which takes this number to around £2.1 billion on a steady state. Is this sort of level of £2.1 billion of free cash flow achievable for FY 2020? Then, I guess, two smaller questions, but we can — maybe I will go back in the queue.
Peter Durman
executiveAll right, thanks, Nico. Here's what I'll do: I'll have Joerg take the first two, the ones about Germany and the UK, and then I'll turn to Oliver for the cash flow question. Thanks.
Joerg Biebernick
executiveHi, Nico. Good morning. Yes, Germany enjoyed several years of quite robust financial results. And it's fair to say our expectations entering the year were higher on share performance too. You might remember we stated our intention to launch Davidoff and capitalize on it, and sadly that did not prove successful. We then experienced ongoing pressure on JPS, which we are now addressing through certain portfolio decisions, and those launches are happening at this point. So we actually anticipate JPS will steady and return to growth. And lastly, as you may be aware, Germany represents a very significant footprint for FCT within our business. We have redirected our sales force toward FCT. That too has begun to stabilize and, most recently, actually delivered quarter-on-quarter share growth in Q2 compared with Q1 in Germany. So we think those decisions are beginning to bear fruit. And regarding the UK, it has not been a cash cow market in the sense that we have grown share there continuously since 2017. We did, however, apply unilateral pricing in spring 2019 and suffered a share decline. That is now turning around, and we are once again observing sequential share growth.
Joerg Biebernick
executiveH1 came in higher than the second half of 2019. At this point we're up against a smaller comparison base. The main thing behind that is we actually have a couple of launches on the FCT side, and those are off to a great start. I'll stop there. So, really, fairly solid performance, particularly on a sequential basis, across both markets.
Nico von Stackelberg
analystSo a quick follow-up question on the UK, if I may. In that market, you ought to see profit growth coming from tobacco, and broadly speaking, it justifies the investment.
Joerg Biebernick
executiveRight, exactly. And in the UK, we've also been growing both the top and bottom line in H1 compared with a year ago. You're absolutely right about that. So this is profitable growth.
Nico von Stackelberg
analystAll right, thank you.
Oliver Tant
executiveOn your cash flow question, Nico, yes — £2.1 billion of free cash flow is entirely achievable given how the current year is shaping up. What I'd like to do, though, is perhaps touch on a few of the developments whose certainty, at this moment, carries somewhat higher forecasting risk. Clearly, in the first half — and we'll carry on doing this in the second half — we made significant progress on the underlying working capital levels we employ, through better inventory management, tighter credit control, and ensuring we stay consistent with our accounts payable policies when working with our suppliers. That said, there's no question COVID has left its mark on working capital deployment. To protect supply, for instance, we've bought additional non-tobacco material stocks for our factories, so that should our supply chain be disrupted, we can bridge longer stretches of interruption to our suppliers' manufacturing capacity using those buffer stocks. In several markets, we've also raised finished goods stock levels in case our ability to supply into market is disrupted.
Oliver Tant
executiveSo overall, our inventory levels are higher. Clearly, how much COVID unwinds and how quickly lockdowns lift will shape how much of those extra buffer stocks we keep and how far they come down going forward. And there's plainly an opportunity for us if there's a bigger unwind, should lockdowns end sooner. The second point I'd make is that government excise duty policy also affects our working capital. There are 2 elements here. As those duties go up, we typically collect from customers before paying customs and excise. So rising duties tend to help our overall working capital position, while if governments decide to recover that duty sooner, that hurts working capital. Depending on how those 2 factors play out over the rest of the year and whether governments use that to affect their overall excise duty receipts, we could see a different impact on our working capital, which is clearly outside our control, and it could range from positive to slightly negative in light of the latter point I made about collecting earlier.
Oliver Tant
executiveOn the CapEx side, it's clear that during the lockdown we weren't able to spend at the level we normally would have. Some of that spending has been pushed back. I think that will mean a lower CapEx outflow across the year. And obviously, between now and year-end, we don't plan to put any meaningful money into any kind of investment activity. So from where I sit right now, the £2.1 million looks like a pretty probable outcome, subject to those COVID cautions.
Nico von Stackelberg
analystThanks, Oliver. I appreciate it.
Operator
operatorAlicia Forry from Investec is up next with a question. The line is open for you.
Alicia Forry
analystMorning, Dominic, Joerg and Oliver. I have three questions, if that's alright. First, I'd appreciate hearing more about what's going on in the non-priority emerging market — we haven't heard much on that — so could you briefly talk about developments there over the last six months and how those markets have performed through the crisis so far? Second, I'd like to follow up on Michael's question regarding duty free. I believe you said duty free overall may carry a lower margin than the group average. Can you confirm if, taken as a whole, it is more or less profitable compared with the group? And last, on the dividend and debt policy changes, was the new CEO consulted on this, or did the board make this move on its own? Thank you.
Peter Durman
executiveAll right, thank you very much, Alicia. Here's what I'll do: I'll have Dominic address the question about how the non-priority emerging markets performed, and after that I'll turn to Oliver to handle the point on duty free profitability, along with the dividend and the new CEO.
Dominic Brisby
executiveYeah. Hello. So when it comes to non-priority emerging markets, I'd say the ones that matter most are likely those in Africa. And broadly, as is typical for our African operations, especially the Sub Saharan African part of the business, performance has come across as extremely resilient and quite strong — in both trading and market share terms. One small caution here: in certain markets, with deeper lockdowns tied to the coronavirus in the very recent period, we've seen market size take a hit, especially since that overlaps with Ramadan as well. So I think that's a factor to keep an eye on in some of these African markets. But for this year so far, our performance has been very satisfactory.
Oliver Tant
executiveNow, regarding duty free margins, they generally run a bit above the company-wide average. Let me unpack the earlier points somewhat. Our travel operations, clearly, consist of 2 parts. One is duty free — those shops in airports, aboard planes and ferries, where travelers are outside the excise duty regime. The second piece is travel retail, in which customers cross a border to purchase duty paid goods in a setting where that trade enjoys a genuine price benefit. Repatriation affects both of these categories — when that opportunity is unavailable, the shopper might buy, and to some extent does buy, inside the country they're departing from. So when we think about losing duty free, we have to weigh the margin effect knowing that this shopper will subsequently purchase in a market where, in all likelihood, our margin is greater than what we'd earn in the market or setting where they'd otherwise be buying — be that via the airport or from the domestic market.
Oliver Tant
executiveOn the upside, I think repatriation could offset most of what the travel restrictions do; on the downside, gross profit could get diluted, though my guess is the margin will land roughly where it is now — likely a bit above what we'd assume if those purchases happened while people were traveling. On Stefan's question: as a board, we've kept Stefan updated and in conversation with him throughout our discussions. Worth pointing out that Stefan isn't on the board yet. He remains a full-time chief executive at Inchcape, and that's where his responsibilities sit at present. Even so, we've been coordinating with him on every material decision we've made, to make sure he's comfortable.
Operator
operatorJon Leinster has the next question. Your line is open.
Jon Leinster
analystThanks. Yeah, I have a few questions, please. First, just to follow up on an earlier one, given the downtrading and the focus on improving market shares, it seems a bit incongruous that you'll be taking some notable price increases in the second half. And just to be clear, do you think overall price mix on the tobacco side will be negative — or flat or negative in the second half? That's the first question. Second, although you've clearly stated your net sales of NGP in terms of — clearly, there's been destocking and so on. What do you think the broad trend will be for your consumer sales for NGP in the first half, because clearly it will be somewhat different given the destocking levels? And lastly, given that you've got to focus on costs and the sort of cost reduction program, the restructuring program previously announced pretty much comes to an end in 2020 — should we expect further announcements with regards to cost reductions and restructuring? Thank you.
Peter Durman
executiveThanks, Jon. So what I'll do, I think, is ask Oliver to handle the first one, on the downtrading and the outlook for that tobacco price mix piece. Then what I think I'll do is ask Dominic and Joerg to say a little about consumer trends in their respective markets, to give you some flavor on that. And then on the last one, the cost program, I'll ask Oliver to cover it. So maybe, to begin with, I'll ask Dominic and Joerg to take the consumer trends one first.
Dominic Brisby
executiveOkay, it makes sense to begin with the USA, given that it's the key market for vapor. On an absolute basis, our share of blu in the US has fallen during the first half. That said, the broader figures are a bit more complicated, so it's worth breaking them down a little. So on an absolute basis, blu's share has gone down. What's interesting is that myblu's share has risen slightly year-on-year — comparing half year with half year, it's up by 54 basis points. But overall, we're down because of the legacy SKUs, which are in long-term terminal decline. That's interesting given that, despite having cut investments substantially and having adopted a very strict stance in the USA, in the AA division and in Europe — namely that we will only put money behind NGP areas where payback comes quickly and is satisfactory — we've ended up redirecting or reducing large amounts of A&P so it goes into the areas where we think the best return is available. One of the US areas where we've done that, and where it has worked rather well, has been making sure we keep a real focus on our online sales.
Dominic Brisby
executiveWhat's interesting is that none of the IRI or Nielsen data you'll come across captures myblu's online sales. That data is store-based. Still, I can share that our online myblu sales grew 58% in the first half compared with last year, and they now account for roughly 25% of our total sales. Joerg?
Joerg Biebernick
executiveThank you, Dominic. Turning to Europe, I'll address both vape and oral nicotine, beginning with vape since that's the priority category. To start, the global category had been hit by the negative headlines that came out of the US last summer, and that affected European category growth, which had been very strong until that point, but the category took a dip through, I'd say, the November/December period, and that affected our sell-out rate. The good news is that the leadership market shares we'd built over the previous 18 months were largely intact in places such as Spain, Italy, and also Germany, where we're battling closely for market leadership. So, we hold 50 share in Italy and that hasn't moved much. In Spain, above 50%. So, that was actually working in our favor. And the second thing we observed was that, as the category came down, loyalty went up. So we now have, I think, more loyal consumers who keep buying our pods and are supporting our share performance. Overall, actually, probably slightly better than anticipated given the investment retrenching we've done. On OND, it's quite a positive story because the category is growing strongly in Austria and in Germany and in the Nordics countries, which are the priority markets, and we are performing very well.
Joerg Biebernick
executiveSince we launched in Austria, which served as our test market, we’ve been the market leader there, and in Germany we hold a share of more than 20. So performance is quite healthy and quite profitable.
Oliver Tant
executiveJon, regarding your third question, it was about the trend in price mix, I believe, and we do expect pricing in the second half of this year. Actually, when we look at the first half, the gross pricing benefit was largely driven by pricing. That took place in the second half of last year, and we expect that to happen — to repeat in H2. So we anticipate some underlying price momentum. Based on our current forecast, that will more than offset any price mix pressures. So we expect that to contribute to our net revenue trajectory. On restructuring cost, the first point to make, probably, is that certain activities we would have looked to undertake in FY 2020 have likely been delayed somewhat by the current crisis, and so, at least in cash cost terms, a number of the initiatives we had advanced would likely now spill over into FY 2021. As for any additional restructuring programs beyond our COPII initiative, at present we have no plans for anything. But obviously we will be reviewing with Stefan's strategic focus, and it really is a bit too early to say whether, as a result of that, since we haven't had those discussions yet, anything might be forthcoming.
Jon Leinster
analystAll right, thank you. So just so I understand correctly, Oliver — what you're saying is that the price mix is likely to turn positive during this year's second half.
Oliver Tant
executiveI'm not going to give a signal here. What I'm saying is that it will probably be positive.
Jon Leinster
analystAlright.
Oliver Tant
executiveOur expectation is that this will come in positive. We aren't anticipating a negative price mix. And we don't anticipate that downtrading's effect will materially offset the gross price benefit we'll see in the second half.
Jon Leinster
analystGreat. All right. Thanks a lot.
Operator
operatorAdam Spielman from Citi has the next question, and your line is open.
Adam Spielman
analystThanks a lot for that question. I want to be sure I've really grasped what you've been telling us, Oliver in particular. On where the investment priorities sit — and if I look back, there was a fairly clear set of them. You had the returns markets, where you weren't really putting money in, and the growth markets, where you were looking to pick up share and NGPs. And after what I'd call mixed results at best from that, it strikes me — and I just want to be certain I have this crystal clear — that your investment focus is now a priority on the top 10 tobacco markets, tilted, if anything, toward lower-end products in tobacco. Then, in NGPs, you're basically very concentrated on getting a short-term sort of benefit from whatever you do, with a bit of an emphasis on what's going on with heated tobacco in Japan and also the sort of oral nicotine products in Germany and Austria. And that has, to some degree, been in line with Stefan. Is that a fair summary of what I've heard, or have I somehow picked things up wrongly?
Oliver Tant
executiveI think to some degree we may need to recalibrate it, Adam. So actually, in Tob Max, our strategy hasn't materially changed. Our strategy has been to focus on our priority markets and our priority brands. And we have 10 markets, which we've always been clear on, represent the majority of our profitability and inevitably, therefore, they draw the majority of the investment. We have a number of brands who tend to outperform the market average and our average and we focus on those brands. What we've clearly done, and I think Dominic referred to this earlier on, is that we've had over the last couple of years a significant focus on our NGP business with sales forces, elements of our marketing teams being focused on the opportunity in EVP. To some degree, we're refocusing that capability on our tobacco business to drive further and better performance out of that business. As regards — and otherwise, not a lot has changed other than the operational and tactical decisions that we're making on a day-to-day basis around the types of initiatives that we're progressing. In terms of NGP, we had a focus with — I think it was phrased in the context of wanting to sort of lead in the context of EVP, to be a fast follower in the other two categories.
Oliver Tant
executiveRegarding OND, our investment thesis remains the same. It's a business that's coming along nicely for us, and the category itself is doing very well. When you look at heated, the investment profile is obviously much more long-term in nature. And we're applying a certain amount of moderation to that spending until we've had a chance to talk it through with Stefan and he's had time to get into the business, understand how it's performing, and better assess his own priorities. We're moderating how much we invest in heated tobacco. And the same thing applies, just to a slightly larger extent, with our EVP business. EVP consumers also include a group we've been recruiting over time whose loyalty has been relatively weak, and we're deprioritizing the focus on essentially bringing those consumers onto the franchise in the near term, in favor of a group whose contribution to performance is much stronger when it comes to our results. So those things combined mean we're reducing investments overall in the current year. In response to your last question from earlier, I think I gave you a sense of the scale of that in terms of second half performance.
Oliver Tant
executiveOn Stefan — he hasn't come in yet, and he hasn't laid out his strategy yet. We're carrying on with a recalibrated take on what our focus was previously, getting things ready. Until we've had the chance to talk with Stefan and he's set out where he wants to concentrate and what his strategy is — after which we'll push ahead over the months and years ahead — we don't want to give up material ground in any of the environments where we operate.
Dominic Brisby
executivePerhaps I can add one more point there. You raised the question of our brand portfolio and the emphasis on tobacco in the value segment, and I think it's worth recognizing that in fact Davidoff turned out to be one of the best-performing brands this year. We've put a considerable amount of effort into the Davidoff brand. As a result, a great deal of our market share gain has come from Davidoff. So it isn't only the others. But obviously, especially in light of what we mentioned regarding downtrading and similar factors, we're likewise taking opportunities to examine how our portfolio could be positioned for the present conditions. So right now that means we're also looking more toward the value end.
Adam Spielman
analystThank you. And may I follow up with a second question? You’ve clearly provided guidance on what you expect the effect to be from the corona crisis and the recession we’re all more or less anticipating. And if you had to estimate where the balance of risk sits, would you say it’s roughly evenly weighted between the downside and the upside of that low-single digit impact? Or would you say — obviously, that’s what you believe is most probable, but do you think the likelihood of performing better than that is higher or lower than the likelihood of performing worse than that, since there’s plainly a considerable amount of forecast risk here?
Oliver Tant
executiveI think it's fair to say, Adam, that forecast risk is inevitable. A second peak is not something we have assumed. Nor have we assumed a whole series of government interventions driven by a second peak across a large number of markets. So that risk exists — we could experience a second peak. We could see some individual initiatives that could have an effect, although we've examined a number of those and we consider them quite remote. At the bottom end of that range, we've tried to be pretty conservative in our judgments. For example, we're actually assuming that the travel environment stays shut until the end of September, with more recent noise over, I guess, the last few days suggesting we might see a little more tolerance toward modest levels of travel taking place. But it's difficult to be confident about how governments are going to react to the crisis at this point in time. And from our perspective, we felt it was important for us to range what we see. We believe we can range what we see. We believe we can do that on the basis of what most people would regard as a sensible set of assumptions.
Oliver Tant
executiveSo you can see the effect falls inside a range we can manage and tolerate. A lot of the problems we're discussing — we don't anticipate that kind of permanence when it comes to the medium-term prognosis for the business.
Adam Spielman
analystAll right, thanks.
Operator
operatorSanath Sudarsan from Morgan Stanley is up next with a question. Your line is open.
Sanath Sudarsan
analystGood morning, everyone. I hope you're all doing well. I'd like to follow up on what Adam said regarding your NGP strategy. As I understand it, much of your new plan appears to center on capping investments and focusing on selected markets where cash flow can be generated more quickly. Could you give us a better sense of how that has shifted your approach to work, to product development, to branding, and to how you work within certain categories? And while we're on the subject, please also shed more light on your approach to tobacco — you mentioned going back to basics on tobacco. What does that mean for operational performance in terms of numbers, if you could give us some detail? That would be great. My second question concerns your path to accelerating deleverage: operationally, it still looks like you're roughly two years away from reaching the lower end of your 2 to 2.5 times net debt to EBITDA. But, of course, the market is more volatile now. Do you have any thoughts on additional strategic asset sales you might be willing to pursue to speed up this deleveraging process?
Sanath Sudarsan
analystI appreciate that.
Peter Durman
executiveThank you so much, Sanath. What I believe I'll do is have Dominic speak to the NGP elements of that — the strategy, more or less, behind the approach there — and maybe also weigh in on the back-to-basics tack on tobacco, though Joerg, you may want to chime in as well regarding your markets and what you're observing on back to basics with tobacco. Then, on the last item, deleverage and so forth, I'll turn it over to Oliver.
Dominic Brisby
executiveThank you. So regarding the NGP strategy, it's important to note that we aren't bringing in a brand-new strategy for NGP; rather, we're sharpening one that already exists. That requires us to be especially mindful. And ever since Joerg and I assumed our roles in February, we've been especially mindful of securing a stronger return on investment for the funds we commit to NGP than we maybe did in the past. What that's meant is being very mindful about where our investment goes, ensuring we achieve an acceptable return on it, and ensuring that return materializes reasonably fast. That applies to our in-market activities and to how we deliver NGP in markets. That said, as you correctly noted, certain activities take far longer and remain essential to continue — around building brands for the long term, around developing products, and around innovation. We've reviewed all of those activities, and in the places where we consider them important and where we believe they can deliver a solid return going forward, we've kept them going. So we still maintain substantial focus on innovating our product portfolio, which we consider essential given what this category is like.
Dominic Brisby
executiveSo that's carrying on. When it comes to the back to basics approach on tobacco, honestly, this is quite straightforward. It's about ensuring we deliver to the consumer what they want and in the manner they want it. It's about ensuring we hold the price points where the consumer is shifting. It's about ensuring our brand identities are very coherent. And it's also about ensuring we're fully distributed wherever the consumer wants to purchase. And in the current coronavirus situation, this matters doubly. In my view, this has produced a better overall tobacco strategy, but also better in market execution too. And the result of this is that for the half year we've managed to grow 7 out of our 10 priority markets, which is something — which I think we've never done before. So it does appear to be bearing fruit.
Joerg Biebernick
executiveYes, and I'd like to add to what Dominic said. I believe the same holds true for Europe. Basically, we aimed to be actively involved wherever the consumer is headed. That required, across several markets, putting more emphasis on FCT from a portfolio standpoint. So we introduced the Horizon brand in Spain. We put money into France, and also into the UK through the Lambert & Butler launch in FCT. We corrected price points and applied them more consistently in markets such as France once again. Beyond that, in-market execution concentrated more on tobacco, honestly, moving away from an emphasis that had been tilted more toward vape over the last year, and that paid off for us too. Because of this, we've now achieved growth — I believe for the first time ever, or at least in a long time — in total market share in Spain, even despite the drag from the dark side. We began growing share in France sequentially once more. Q2 share in Germany came in ahead of Q1. And in the UK, as already noted, we're likewise growing sequential share on top of the results we'd had in Italy for some time already. So on the whole, all of those — ultimately, straightforward actions are helping to fuel performance.
Oliver Tant
executiveTurning to the deleverage path — earlier in the conversation we discussed how much free cash flow we think we can produce. Over the 12 months ending at the half year, we generated roughly £2.4 billion to £2.5 billion of cash flow. Within that same 12-month span, we put about £450 million to work, share buyback included. Given where things stand now, and the fact that Stefan will need some time to review his strategy and settle on his focus, we definitely don't see ourselves matching that pace of investment as far as M&A and share buyback activity go in the short to medium term. On top of that, we're cutting dividends by £650 million on an annualized basis. We also expect roughly £1 billion of cash coming in from the PCD sale. So my view is that over a two-year stretch we'd anticipate possibly £500 million to £600 million less in investment outflow compared with the trend of the last 12 months, plus about £650 million a year of lower — of reduced dividend outflow. Clearly, we gain from higher operational cash inflow. And we gain from the PCD disposal, with £1 billion flowing in.
Oliver Tant
executiveI think it is — I would expect that deleverage, assuming we don't get any further interruptions to our cash flow, enforced exogenously to largely enable us to reach that objective over the two-year period, and hence the statement that we've made in the RNS. I'm not anticipating that we would need to engage in any form of realization activity in order to drive that trajectory.
Sanath Sudarsan
analystWell, thank you so much.
Operator
operatorThe next question is from Patrick Dolan of Redburn. Your line is open.
Patrick Dolan
unknownOkay, thanks. Good morning. I have just a couple of questions. First, you brought up downtrading in the US. Could you give us some detail on the deep discount segment and how it has developed over the past few months, plus any insight into how the Sonoma brand has done compared with that segment? Then, regarding the menthol ban that takes effect tomorrow, will you be doing the buyback soon for any of the menthol cigarettes after the ban? And if you are, what effect does that have on margins?
Peter Durman
executiveAlright, many thanks, Patrick. First, I’ll have Dominic cover what’s driving downgrading in the US and how the Sonoma brand is performing in that context. After that, I’ll turn it to Joerg to discuss the menthol ban in Europe. Dominic, over to you.
Dominic Brisby
executiveYeah, thanks for that. Downtrading in the US is still happening, and it has carried on through this coronavirus period, but I wouldn't say it has altered or sharply worsened the broader trend that existed beforehand. Sonoma has done especially well. It's up 20%, and it's gaining share within the segment and, of course, within a segment that is growing, which has been one of the things driving our share growth in absolute terms at the half year in the U.S. It's also worth mentioning, though, that several of our brands, including ones in higher price segments, such as Kool, even though some of them are losing share in absolute terms, are growing within that price segment. So, the action and the decisive work we've taken on our brand propositions and our distribution has meant that, overall, our U.S. portfolio is in pretty good shape, as well as delivering a cigarette price mix of 5%. So, we're quite satisfied with our U.S. performance.
Joerg Biebernick
executiveThanks, Dominic. Now regarding menthol, it makes up a fairly modest portion of what we do in Europe — roughly 3% to 4% of volumes. We really don't anticipate the ban having much of an effect, since we think most consumers will probably remain in tobacco and stick with the brands they currently use. With that in mind, we've introduced several variants across our major brands to support that shift away from menthol toward a future. On top of that, clearly, we're very interested in moving consumers toward potentially risk-reduced products as well. And blu comes in menthol flavor. We've also launched — particularly in the UK — our Rizla flavor cards, so consumers can tailor their experience with those high-quality products. And overall, we don't anticipate a significant impact.
Operator
operatorMoving on, our following question is from Nico Von Stackelberg at Liberum. Your line is open.
Nico von Stackelberg
analystAppreciate that last question. Someone raised a point earlier about — I believe it concerned NGP optionality. That got me thinking — perhaps you're considering a sale of part or all of NGP, and I don't believe that's necessarily the situation, since another remark came near the end that you don't see a need to divest assets in order to sort of hit the target. So I suppose the question, stepping back, is this: you managed to dispose of the Premium Cigars business at a reasonable multiple, clearly above the group's multiple. Does that leave room for Imperial to revisit its broader divestment program? Or does that perhaps run ahead of whatever ideas Stefan might have? Thanks.
Peter Durman
executiveThanks, Nico. I’ll have Oliver respond to those points.
Oliver Tant
executiveRight. Look, once Stefan has had more time to get a fuller picture of the business overall, we need to sit down with him and discuss where his focus and priorities lie. What we can say right now is that, over the short term, we don't intend to carry out any further divestitures. Obviously, once we've settled on that focus and held the wider discussions on capital allocation, we'll give you an update at that point, but updating at this stage isn't appropriate. We can't, because we're still going through the transition and will be for some time yet, in terms of onboarding Stefan, working out the strategy, and then weighing what that means on the capital allocation side. What I think I can say is that the program we discussed in May of 2018, involving the disposal of PCD, has basically come to an end. Gross proceeds came to roughly £1.5 billion, against up to £2 billion, which was what we stated at the time.
Nico von Stackelberg
analystThanks a lot. I appreciate that.
Operator
operatorAlicia Forry from Investec is up next with a question. Your line is open, so please go ahead and ask.
Alicia Forry
analystHello, and thank you — I just have a quick follow-up question. You mentioned that Stefan has been in a trailer process for some time. Could you share anything about the anticipated schedule for him to lay out his new strategy and vision? My sense is that the market may have been expecting this to surface at the full-year results presentation in November, though based on what you've said, that perhaps looks a little early. At the same time, holding off until this same point next year would seem too long. So is there any plan for something like a Capital Markets Day or another event through which he could share his new vision with all of us?
Peter Durman
executiveI’ll have Dominic answer that one. Thanks, Alicia.
Dominic Brisby
executiveHello. I believe it's too early to guess when Stefan might decide to take that step. So, keep in mind that Stefan remains an active CEO at Inchcape. We're eager to have him join the business on July 1. But as with any incoming CEO, Stefan will require some time to determine his strategic priorities and how he wishes to operate the business. So, I think it will fall to Stefan to update you on the timing for that after he has come on board at some point.
Operator
operatorThat wraps up the question portion. Thank you, and please go ahead.
Peter Durman
executiveAlright, that just leaves me to say thanks to everyone for being on the call today. And thanks for the questions you raised. And of course, the IR team will be available throughout the rest of the day should you have anything more. Many thanks. Goodbye.
Operator
operatorThat brings today's conference to a close. Thanks to everyone for joining us. You can all disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Imperial Brands PLC transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Imperial Brands PLC earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Imperial Brands PLC or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.